Health Care·Biotechnology·$8.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.51 | N/A | -8.51% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.51 | N/A | -8.51% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing development efforts.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on advancing its clinical programs despite the earnings miss.
Vaxcyte Inc's earnings report showed a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's near-term performance. Overall, the market reacted cautiously to the news, reflecting uncertainty about future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
US FOODS HLDG CORP
Nov 8, 2021